medigraphic.com
Instituto Nacional de Salud Pública

2022, Number 2

<< Back Next >>

salud publica mex 2022; 64 (2)

Cost analysis of drug treatment in hypertensive patients at social security health care family medicine units

Figueroa-García J, Granados-García V, Roldán-Valadez E, Rojano-Mejía D, Cruz-Toledo JE, Palomo-Piñón S

Language: English
References: 25
Page: 188-195
PDF size: 265.91 Kb.


ABSTRACT

Objective. To estimate the increase of drug treatment costs associated with predictive factors of hypertensive patients in family medicine units. Materials and methods. A generalized linear model was employed to estimate costs with data from a microcosting costing study for a 1-year time horizon. Sources of dada were medical electronic files, pharmacy records and unitary prices updated to 2019. Results. From a total of 864 patients older than 65 years were 67% and women 65%. Factors with most influence on mean drug treatment costs were diabetes, age and complications associated with hypertension. Mean annual cost of antihypertensive treatment was 61 dollars (CI95% 55,67) and median were 32 dollars (IQR 30,35) per patient. Incremental costs for diabetes were 23 dollars (CI95% 13,33) and 10 dollars (CI95% 8.3,12) in the group of ≥ 65 years. Conclusion. Diabetes, age and complications were the factors with largest influence on hypertension pharmacological costs.


REFERENCES

  1. World Health Organization. Noncommunicable diseases: WHO, 2018 [cited 2019 September 3]. Available from: https://www.who.int/es/newsroom/ fact-sheets/detail/noncommunicable-diseases

  2. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012;380(9859):2224-60. https://doi.org/10.1016/S0140- 6736(12)61766-8

  3. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441-50. https://doi.org/10.1161/CIRCULATIONAHA. 115.018912

  4. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-37. https://doi.org/10.1038/s41581-019-0244-2

  5. Shamah-Levy T, Heredia-Hernández O, Romero-Martínez M, Mojica- Cuevas J, Cuevas-Nasu L, Santaella-Castell JA, Rivera-Dommarco J. Encuesta Nacional de Salud y Nutrición 2018-19: Resultados Nacionales. Cuernavaca: Instituto Nacional de Salud Pública, 2020 [cited 2019 Sept 3]. Available from: https://ensanut.insp.mx/encuestas/ensanut2018/doctos/ informes/ensanut_2018_informe_final.pdf

  6. Shamah-Levy T, Ruiz-Matus C, Rivera-Dommarco J, Kuri-Morales P, Cuevas-Nasu L, Jiménez-Corona M, et al. Encuesta Nacional de Salud y Nutrición de Medio Camino 2016. Resultados Nacionales. Cuernavaca: Instituto Nacional de Salud Pública, 2017 [cited 2019 Sept 3]. Available from: https://www.insp.mx/images/stories/2017/Avisos/docs/180315_encuesta_ nacional_de_salud_y_nutricion_de_medio_Ca.pdf

  7. Chan M. A global brief on hypertension Geneva: WHO, 2013 [cited 2019 September 3]. Available from: https://www.who.int/cardiovascular_ diseases/publications/global_brief_hypertension/en/

  8. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. Jama. 2017;317(2):165-82. https://doi. org/10.1001/jama.2016.19043

  9. Arredondo A, Aviles R. Costs and epidemiological changes of chronic diseases: implications and challenges for health systems. PLoS One. 2015;10(3):e0118611. https://doi.org/10.1371/journal.pone.0118611

  10. Instituto Mexicano del Seguro Social. Programa Institucional del Instituto Mexicano del Seguro Social 2014-2018. 2014. Meixco City: IMSS, 2014 [cited 2019 September 3]. Available from: http://www.imss.gob.mx/ sites/all/statics/pdf/PIIMSS_2014-2018_FINAL_230414.pdf

  11. Instituto Mexicano del Seguro Social. Evaluación de los Riesgos Considerados en el Programa de Administración de Riesgos Institucionales 2010. Mexico City: IMSS, 2010 [cited 2019 September 3]. Available from: http:// www.imss.gob.mx/sites/all/statics/pdf/estadisticas/PARI/parievaluacion2010.pdf

  12. Arredondo A, Avilés R. Hypertension and its effects on the economy of the health system for patients and society: suggestions for developing countries. Am J Hypertens. 2014;27(4):635-6. https://doi.org/10.1093/ajh/hpu010

  13. Villarreal-Ríos E, Mathew-Quiroz A, Garza-Elizondo ME, Núñez-Rocha G, Salinas-Martínez AM, Gallegos-Handal M. Costo de la atención de la hipertensión arterial y su impacto en el presupuesto destinado a la salud en México. Salud Publica Mex. 2002;44(1):7-13.

  14. Lipscomb J, Yabroff KR, Brown ML, Lawrence W, Barnett PG. Health care costing: data, methods, current applications. Med Care. 2009;47(7):S1- S6. https://doi.org/10.1097/mlr.0b013e3181a7e401

  15. Organizazión Mundial de la Salud. Soluciones de bajo costo para luchar contra las enfermedades no transmisibles. Geneva: OMS, 2011 [cited 2019 September 3]. Available from: https://www.who.int/mediacentre/news/ releases/2011/NCDs_solutions_20110918/es/

  16. Adane E, Atnafu A, Aschalew AY. The Cost of illness of hypertension and associated factors at the University of Gondar Comprehensive Specialized Hospital Northwest Ethiopia, 2018. Clinicoecon Outcomes Res. 2020;12:133-40. https://doi.org/10.2147/CEOR.S234674

  17. Wang G, Yan L, Ayala C, George MG, Fang J. Hypertension-associated expenditures for medication among US adults. Am J Hypertens. 2013;26(11):1295-302. https://doi.org/10.1093/ajh/hpt079

  18. Park C, Wang G, Ng BP, Fang J, Durthaler JM, Ayala C. The uses and expenses of antihypertensive medications among hypertensive adults. Res Social Adm Pharm. 2020;16(2):183-9. https://doi.org/10.1016/j. sapharm.2019.05.002

  19. Saez M, Barceló M. Coste de la hipertensión arterial en España. Hipertens Riesgo Vasc. 2012;29(4):145-51. https://doi.org/10.1016/j.hipert.2012.07.003

  20. Arredondo A, Damián T. The economic costs in the production of health services: from the cost of inputs to the cost of case management. Salud Publica Mex. 1997;39(2):117-24.

  21. Park C, Wang G, Ng BP, Fang J, Durthaler JM, Ayala C. The uses and expenses of antihypertensive medications among hypertensive adults. Res Social Adm Pharm. 2020;16(2):183-9. https://doi.org/10.1016/j. sapharm.2019.05.002

  22. Wang G, Zhou X, Zhuo X, Zhang P. Annual total medical expenditures associated with hypertension by diabetes status in US adults. Am J Prev Med. 2017;53(6):S182-S9. https://doi.org/10.1016/j.amepre.2017.07.018

  23. Instituto Mexicano del Seguro Social. Portal de compras [Internet]. IMSS, 2018 [cited 2019 September 3]. Available from: http://compras.imss. gob.mx/?P=imsscompro

  24. Deb P, Norton EC. Modeling health care expenditures and use. Annu Rev Public Health. 2018;39(1):489-505. https://doi.org/10.1146/annurevpublhealth- 040617-013517

  25. Jones AM. Models for health care. University of York, Centre for Health Economics. 2010;10(1):1-31 [cited 2019 Sept 3]. Available from: https:// www.york.ac.uk/media/economics/documents/herc/wp/10_01.pdf




2020     |     www.medigraphic.com